However irksome it may be to think about open or healing wounds, the medical advances and market potential in this niche space is quite appealing for investors. Globally, there are 50 million reported cases of patients suffering from some type of wound that may be difficult to close or heal.
Delmar Pharmaceuticals (DMPI) is a clinical and early stage Oncologyl Company focused on developing and commercializing leading anti-cancer therapies in high impact orphan oncological indications specifically where patients have failed contemporary therapy.
Pressure Biosciences (PBIO) is a life sciences company centered on developing and commercializing a novel technology titled Pressure Cycling Technology (PCT).
Athersys (ATHX) is a clinical stage based biopharmaceutical company with an exponentially growing pipeline and an array of products in therapeutics to treat significant and life-threatening diseases.
A company to keep a look out for in the upcoming future is BioDelivery Sciences International (BDSI), a specialty pharmaceutical company with a platform of drug delivery technologies to develop, commercialize, and improve already proven applications of therapeutics.
Pluristem Therapeutics (PSTI) is a developer of placenta-based cell therapies. They have just formed a strategic alliance with Cha Bio&Diostech.
Novavax, Inc (NVAX) is a clinical-stage biopharmaceutical company that strives to create novel vaccines to treat a broad spectrum of diseases around the world.
Orexo is an emerging specialty pharmaceutical company in route to enter the market with their new medication Zubsolv; an oral medication that dissolves under the tongue to treat opioid addiction.
AVEO Pharmaceuticals’ (AVEO) New Drug Application (NDA) with the FDA for their newly developed once a day oral medication to fight advanced renal cell carcinoma – known as Tivozanib – has hit a snag.Upon review, the FDA’s Oncologic Drugs Advisory Committee voted 13-1 against approval due to safety concerns.
Copyright © 2024 | WordPress Theme by MH Themes